

Index

A

- ACD, 230, 587
Acneiform rash, 756–758
Acral lentiginous melanoma (ALM), 412
 cell of origin, 357
 initiating and characteristic oncogenic events, 355–357
Acral melanoma, 412–435
 definition and epidemiology, 412–413
 genetic alterations, 414–417
 management and prognosis, 433–435
 mutational landscape, 416–417
 nail apparatus, 430–433
 on palms and soles, 417–429
 pathogenesis, 413
Activities of daily living (ADLs), 745
Adenovirus, 709
Adjuvant radiation, 796
Adjuvant therapy
 biochemotherapy, 721, 728–730
 checkpoint inhibitors, 731–734
 indications, 718
 interferons, 721
 predictive biomarkers, 719
 prognostication, 718–719
 prognostic biomarkers, 720
 radiotherapy, 720
 signaling inhibitors, 734–735
 vaccines, 730–731
Adoptive cell therapy (ACT), 652, 653, 661
Adverse events (AEs)
 chemotherapy-induced, 762–766
 CTCAE grading system, 745
 cutaneous AE, 745–755
 ircAEs, 745–755
 targeted therapy, 755–762
AKT, 68
Allolectin-7 (Vical Inc), 526, 730
Alpha diversity, 292
American Joint Committee on Cancer (AJCC),
 locoregional disease, 516
American Joint Committee on Cancer (AJCC) melanoma
 staging system, 486, 489
 conditional survival, 496
 distant metastasis assessment, 491–492
 primary tumor assessment, 486–489
 regional lymph node assessment, 489–491
 survival analysis, 496
Angiogenesis, 150, 152, 156, 157
Anti-CTLA-4 inhibition, 655–656
Anti-CTLA-4 therapy, 574
Anti-melanoma immunity, requirements for, 653–654
Anti-PD-1 inhibition, 656
Arnold-Chiari malformation, 376
Arthralgias, 810
Artificial intelligence
 applications in malignant melanoma, 610
 barriers to implementation and limitation, melanoma
 diagnosis, 617–618
 clinical integration, 620
 comprehensive data, 619
 consumer opinion, 616
 definition, 601
 dermatological image databases, 609
 dermatology, 608
 electronic health records, 604–605
 imaging databases, 608–609
 medical imaging, 605–608
 mobile apps, 616
 ophthalmology, 607
 pathology, 607–608
 potential harms, 618
 radiology, 606
 regulation, melanoma diagnosis, 618
 resilience and generalizability, 620
 role in melanoma diagnosis, 616–618
Attention deficit hyperactivity disorder, 375
Atypical Spitz tumor, 399
 molecular diagnostics, 635, 636, 640
AURKA, 415
Australian SunSmart program, 275
Autoimmune hepatitis, 803
Autophagy, 107, 111, 116, 118
5'-Aza-2'-Deoxycytidine (5-Aza), 88
- ## B
- Bacille Calmette-Guérin (BCG), 524
BAP1, 211–213, 228, 404, 456, 586–587, 631, 635, 640
BBB, *see* Blood brain barrier (BBB)

- Beta diversity, 292
 Biochemotherapy, 721
 Blood brain barrier (BBB), 540–542
 Blue nevi, 137
 cell of origin, 351
 clinical and histologic presentation, 350–351
 definition, 349–350
 initiating oncogenic event, 351
 risk for melanoma, 351–352
 Body surface area (BSA), 747, 754
 BRAF, 65–67, 166, 304, 312, 313, 318, 322, 416
 dabrafenib, 671, 674, 676, 681
 fusion, 631
 + MEK inhibition, 673–675, 775
 mutant melanoma, 681
 and NRAS mutations, 167
 and RAS, 167
 resistance, 675–677
 trametinib, 673, 674, 676, 678, 680, 681
 V600, 677
 vemurafenib, 671, 672, 674, 676, 681
 BRAF inhibitor (BRAFi), 572, 735, 755, 756, 758, 761, 763, 766
 therapy, 691
 Brain tumor assessments, 572
BRCA1, 589
BRCA2, 589
 Breslow thickness, 486, 488
 Brg/Brahma-associated factors (BAF) complex, 93
 Bromodomain (BrD), 91
 Bullous pemphigoid (BP), 753–754
- C**
 Cancer survivorship, 813
 Canine melanoma models, 321, 322
 Carcinoembryonic antigen (CEA) gene, 701
 Cardiac toxicities, 778
 Cardiotoxicity, 807
 β -Catenin, 74–75, 319
 C-C chemokine receptor 4 (CCR4), 542
CCND1, 414
 CDK4/6, 71–72
CDK4, 586
CDKN2A, 227–228, 403–404, 414
 Cell line xenografts, 305
 Central nervous system metastases, 811–812
CHEK2 gene, 589
 Chemotherapy, 546, 800
 Chemotherapy-induced cutaneous adverse events, 762–766
 hypersensitivity, 766
 phototoxicity, 766
 Chimeric antigen receptors (CAR), 661
 Chromatin interacting protein complexes, 93–94
 Chromosomal copy number alterations in melanoma, 128, 138, 630, 631, 633, 635, 639, 646
 Class activation maps, 616
Clostridium difficile colitis, 297
 CNS melanoma, 376, 390–391
 Cobas[®] 4800 BRAF V600, 808
 Cobimetinib, 172
 Collaborative Ocular Melanoma Study (COMS), 461
 Colorectal cancer, 292
 Combination immune checkpoint inhibition, 656–657
 Common acquired nevi
 cell of origin, 344
 clinical and histologic features, 339–344
 initiating oncogenic events, 344
 risk for melanoma, 345
 senescence and factors, 344–345
 Common Terminology Criteria for Adverse Events (CTCAE), 745, 748–755, 763
 Comparative genomic hybridization (CGH), 630–636, 641, 645
 Comprehensive integrative analysis
 epigenetic analysis, 204
 genomic classification, 190
 integrative pathway analysis, 194
 mRNA expression signatures, 202–204
 structural aberrations, in melanoma, 196
 Confetti/Brainbow mouse line, 310
 Congenital melanocytic nevus (CMN)
 cell of origin, 348
 classification for clinical management, 368–369
 clinical and histologic presentation, 345–347
 clinical features, 373–379
 cutaneous classification, 367
 cutaneous features, 373–375
 definition, 345, 366
 dermoscopy features in, 378–379
 endocrinological and metabolic abnormalities, 377–378
 epidemiology, 370–371
 ethnicity, gender and environmental factors, 371
 facial features in, 377
 genetic testing, 383–387
 genotypic classification, 367
 germline predisposition, 373
 histopathological features, 379–383
 incidence, 371
 initiating oncogenic event, 347–348
 management, 387–391
 melanoma in, 371
 melanoma risk, 349
 mosaicism, 372
 mutations in, 372–373
 naevus spilus type, 370
 neurological manifestations, 375–378
 pathogenesis of, 372–373
 rhabdomyosarcoma, 378
 senescence and factors, 349
 tardive, 370
 Congenital nevi, 137, 366–392
 Conjunctival melanocytic neoplasms, 136–137
 Conjunctival melanoma, 459–460
 clinical features, 459
 cytogenetic abnormalities, 457

- histopathology, 458
 - metastatic disease, 463
 - molecular pathology, 456
 - ocular investigations, 461
 - systemic investigations, 464
 - treatment, 462
 - treatment for metastatic disease, 464
 - Content based image retrieval (CBIR), 616
 - Convolutional neural networks, 602, 614
 - Copy-neutral rearrangements, 128–130
 - Copy number variations (CNV), 128, 630, 631, 633, 635, 639, 646
 - cutaneous melanoma, 184
 - uveal melanoma, 210
 - Coxsackievirus A21 (CVA21), 708
 - CpG-island methylator phenotype (CIMP), 204
 - C → T mutations, 54, 55, 59
 - Culturomics, 292
 - Cutaneous adverse events
 - chemotherapy-induced, 762–766
 - ircAEs, 745–755
 - targeted therapy, 755–762
 - Cutaneous melanoma, 250, 257, 390
 - Australian SunSmart program, 275
 - copy number variations, 184
 - first generation sequencing, 183–184
 - gender and calendar period, 254–255
 - genomic classification, 190–194
 - early detection, 280
 - economics of prevention, 277–278
 - German screening program, 280–281
 - hats/clothing/shade, 277
 - histologic subtypes, 494
 - historical background, 273
 - host susceptibility factors, 260–263
 - hotspot non-coding mutations, 189–190
 - integrative epigenetic analysis, 194–196
 - integrative pathway analysis, 194–196
 - international variation, 250–251
 - interventions on melanoma rates, 278
 - medical conditions, 263–264
 - mRNA expression profiles, 199–201
 - non-coding RNA, 207–208
 - population health interventions, 274
 - race and ethnicity, 252–254
 - recurrent synonymous mutations, 190
 - risk prediction models, 263
 - screening, 281, 282
 - solar and artificial UV radiation, 258–260
 - solar UV index, 273–274
 - stage groupings for, 493
 - structural aberrations, 196
 - sunbeds, 278–280
 - sunscreens, 276–277
 - survival, 256
 - targeted screening program, 281–282
 - temporal acquisition of mutations and tumor heterogeneity, 196–198
 - TNM staging for, 487
 - transcriptions factors, 198–199
 - U.S. population-based data, 251–252
 - whole exome and whole genome sequencing, 184–189
 - Cutaneous toxicities, 766
 - Cyclin dependent kinase 4 (*CDK4*), 228
 - Cytotoxic therapy, 652, 688
 - Cytotoxic T-lymphocyte associated antigen 4 (CTLA4), 654, 655, 745, 778
- D**
- Dabrafenib, 170, 798
 - Dandy-Walker malformation, 376
 - Dasatinib, 735
 - Data mining, 602
 - Dct::LacZ mice, 309–310
 - DecisionDx-Melanoma, 201, 720
 - DeCOG-SLT study, 511
 - Deep learning classification model, 604
 - Dermal melanocytosis, 349, 351
 - Dermoscopic diagnosis of melanoma
 - on nail apparatus, 431–432
 - on palms and soles, 418–425
 - Desmoplastic melanoma (DM), 134, 479, 480, 720
 - clinical features, 471
 - differential diagnosis, 475–477
 - FNB features, 474
 - genetic features, 475
 - histopathological features, 471–473
 - immunohistochemistry, 474–475
 - prognosis, 478
 - radiotherapy, 477–478
 - sentinel lymph node biopsy, 477
 - surgery, 477
 - systemic therapy, 478
 - Dietary intervention, 298
 - Distant metastasis assessment, 491
 - DNA copy number changes, 128, 405, 406, 630, 631, 633, 635, 639, 646
 - DNA demethylation, 88
 - DNA methylation, 85
 - DNA methyltransferase (DNMT) enzyme, 85
 - DNA methyltransferase (DNMT) inhibitors, 89
 - DNA photoproducts, 54, 56, 58
 - DNA repair, 236–237
 - DNA sequencing, 638
 - Dormancy, 149
 - in metastatic melanoma, 149–151
 - Driver mutation analysis, 385–386
 - Driver mutations, 182
 - Drug reaction with eosinophilia and systemic syndromes (DRESS), 754, 756
 - Dysplastic nevi, 340, 345
- E**
- Eczematous eruptions, 747
 - Edn3 receptor, 12
 - EIF1AX, 456

- Electronic health records, 604–605
 Embryonic development, 4, 5, 14
 Embryonic stem (ES) cells, 6
 Encorafenib, 171
 Endocrine toxicity, 784
 Endocrinopathies, 804
 Endothelin receptor B (EdnrB), 12, 320, 540
 Endothelins, 540
 Epidermal tumors, 759–760
 Epigenetics, 84, 644
 Epigenetic silencing, tumor suppressor genes, 85–87
 Epithelial-mesenchymal-transition transcription factors (EMT-TFs), 199
 Equine melanoma models, 322, 323
 ERK1/2 pathway, 65–67
 ERK inhibitors, 172
 Eumelanin, 25
 Excision technique
 margins of surgical resection, 503–506
 sentinel node biopsy, 506–508
 Exome sequencing, 230, 240
 Extracranial metastases (ECMs), 536
 EZH2, 206
- F**
- Familial atypical multiple mole melanoma syndrome (FAMMM), 585
 FDG PET/CT, immunotherapy response, 573
 FDG PET imaging, 563
 sentinel lymph nodes, 565–566
 surveillance role, 577
 Fecal microbiota transplant (FMT), 297
 Fine needle aspiration biopsy (FNAB), 211, 474
 Flat-topped proliferations, 374
 Fluorescence in situ hybridization (FISH), 632,
 636–637, 645
 limitations of, 638
 vs. myPath[®] gene expression, 641
 prognosis, 637–638
 Fluorescent imaging, for sentinel lymph nodes, 567
 Folliculitis, 756–758
 FoxD3, 10
 Free hand SPECT system, 565
 Fusion kinase, 402, 403, 406
- G**
- Gastric cancer, 292
 Gastrointestinal (GI) effects, 802
 Gastrointestinal toxicity, 781, 782
 Gastrointestinal (GI) tract, 294
 Gene expression analysis, 640–641
 limitations, 641–642
 myPath[®] gene expression vs. FISH, 641
 non-invasive, 641
 prognosis, 642
 Genetically engineered mouse (GEM) models, 307
 Genetic counselling, CMN, 386–387
- Genetic discrimination protections, resources for, 592
 Genetics of melanoma, 138, 140
 Genetics of nevi, 134
 Genetic testing technology, 591–592
 impact of, 593–594
 test results, 592–593
 Genome-wide association studies (GWAS), 231–232
 Genomics, 344, 352, 355, 357, 359, 360
 German screening program, 280
 Glabrous skin, 134, 412
 GNA11, 69, 455
 GNAQ, 69, 455
 Graft-versus-host disease (GVHD), 659
 Granulocyte-macrophage colony stimulating factor (GM-CSF), 700
 GTPase activating protein (GAPs), 168
 Gut-associated lymphoid tissue (GALT), 289
 Gut dysbiosis, 294
 Gut microbiota, 289, 298
- H**
- H3K27me3, 644
 Hand-foot reaction, 760–761, 763
 Head and neck MM (HNMM), 442, 449
 Health insurance discrimination, 593
 Hepatic toxicity, 782, 783
 Hepatocellular carcinoma (HCC), 294
 Hereditary melanoma, risk assessment, 589–591
 High cumulative sun-induced damage (high-CSD) melanomas, 133–134
 High-dose IFN- α (HDI), 721, 728, 729
 High-dose interleukin 2 (HD IL-2), 654–655
 Histone deacetylase (HDAC) inhibitors, 91–93
 Histone modifications, 89–91
 Histone variants, 93
 Hotspot mutation, 182
 Hotspot promoter mutations, 190
 HOX transcript antisense RNA (HOTAIR), 95
 HRAS, 402, 630, 631, 635
 5-Hydroxymethylcytosine (5-hmC), 89, 644
 Hypersensitivity, 766
 Hyperthermic isolated limb perfusion (HILP), 521
 Hypophysitis, 804
 Hypoxia, 100, 104, 107, 113, 116, 118
- I**
- Imatinib, 176, 735
 Imlygic[®], 730
 Immune checkpoint(s), 654
 blockade, 294, 295, 297
 Immune checkpoint inhibitors (ICIs), 745, 749,
 751, 755, 779
 Immune-related adverse events (irAEs), 656, 657,
 745–746, 797
 bullous pemphigoid (BP)-like reaction, 753–754
 cardiotoxicity, 807
 endocrine-relates, 804

gastrointestinal (GI) effects, 802
 immune toxicity, 803
 lichen planus/lichenoid eruption, 752–753
 nephritis, 807
 neurologic toxicity, 806
 ocular and orbital toxicity, 807
 overarching principles, 746–747
 pneumonitis, 803
 pruritus, 747–752
 rash, 747
 SCARs, 754–755
 skin, 802
 vitiligo, 752–753
 xerostomia and mucositis, 806

Immune toxicity, 803
 Immunogenic cell death, 703–704
 Immunohistochemistry, 474–475, 643
 and epigenetics, 644
 genetic alterations, detection of, 644–645
 for immune checkpoint blockade, 645
 Immunohistochemistry (IHC), 658
 Immuno-oncology, 175
 Immunotherapy, 548–549, 572
 and chemotherapy combination, 688–689
 FDG PET/CT, 573
 and targeted therapy combination, 689–690
 toxicity of, imaging, 574
 with anti-PD1 antibodies, 688

Incidence, cutaneous melanoma, *see* Cutaneous melanoma
 Indocyanine (ICG) dye method, 562
 Inflammatory bowel disease (IBD), 289
 Interferons (IFN- α), 721, 797
 Intergroup Melanoma Surgical Trial, 503
 Interleukin-2, 800
 International Agency for Research on Cancer (IARC), 251
 International Skin Imaging Collaboration (ISIC), 610
 Intralesional cytokines, 524
 Intralesional therapy, 524
 In-transit metastases, 491
 Intraparenchymal melanosis, 376
 Ipilimumab, 655, 659, 731, 745, 797
 Ipilimumab and vemurafenib combination, 690
 Isolated limb infusion (ILI), 521, 523
 Isoprenyl cysteine methyltransferase, 167

J

Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, 539–540
 Juvenile melanoma, 396

K

KIT, 415, 681
 inhibitors, 176
 mutations, 136, 415–416, 446, 449
 KSR proteins, 166

L

Laboratory markers, 492
 Lactate dehydrogenase (LDH) levels, 492
LacZ gene, 309
 Lentigo maligna melanoma (LMM), 354
 Leptomeningeal disease, 376
 Leptomeningeal melanocytosis, 345
 Lichen planus (LP)/lichenoid eruption, 753
 Limb perfusion and infusion, 796
 Lineage specification, 7, 10, 12
 Liquid biopsy approach, 495
 Local invasion, 148, 149, 151–153
 Locoregional recurrent melanoma
 combining intralesional therapies, 529
 definition, 516
 initial evaluation, 517–519
 lymphoscintigraphy, 517
 radiation, 527
 randomized controlled trial, 516
 systemic therapies, 528
 topical agents, 527
 treatment options, 519–529
 ultrasound imaging, 517
 unknown primary evaluation, 518
 Long non-coding RNA (lncRNA), 94, 208
 Low cumulative-sun-damage (low-CSD) melanocytic neoplasm, 131–133, 358
 Lung metastases, removal of, 576–577
 Lymphangiogenesis, 151, 153, 155, 158, 159
 Lymphatic mapping technique, 490
 Lymphatic vessels, 151, 153, 156
 Lymphoscintigraphy, 561, 562, 565

M

Machine learning, 601
 Major histocompatibility complex (MHC), 658
 Malignant Spitz tumor
 clinical features, 401
 clinical management, 401
 definition, 400
 histopathologic features, 401
 Masson bodies, 380
 Mass spectrometry, 645
 MBM, *see* Melanoma brain metastasis (MBMs)
 MEK inhibitor (MEKi), 172, 176, 673, 735, 755, 756, 758, 760, 762, 765
 Melanin, 22, 25
 Melanoblasts, 7, 379
 Melanocortin 1 receptor (MC1R) mutation, 30, 34, 36, 40, 43, 44, 65, 588
 Melanocyte, 4, 23–27, 55
 metabolism, 104–106
 stem cells, 31, 32
 Melanocytic neoplasia
 epithelial melanocytes, 130
 MAPK/G α q signaling, activation of, 139–141
 mutational processes, 124–127
 non-epithelial melanocytes, 137

- Melanocytic neoplasia (*cont.*)
 p16/cyclin/CDK/Rb pathway, disruption of, 141
 structural alterations, 127–130
 telomerase activity, 141
- Melanocytic neoplasia, molecular diagnostics
 DNA based testing, 630–640
 protein based testing, 643–645
 RNA based testing, 640–643
- Melanocytomas, 138
- Melanocytosis, 376
- Melanoma-associated antigen 1 (MAGEA1), 88
- Melanoma brain metastasis (MBMs)
 blood brain barrier, 540–542
 brain capillaries, 542
 cancer cells, 536
 CCR4, 542
 chemotherapy, 546
 clinical imaging, 543
 dabrafenib and trametinib, 530
 endothelins, 540
 extracranial metastases, 536
 immunosuppression, 543
 immunotherapy, 548–549
 ipilimumab and nivolumab, 549
 JAK-STAT pathway, 539–540
 MAPK pathway, 537–538
 microarray analyses, 537
 miRNA expression, 542
 PI3K-AKT pathway, 538–539, 550
 pro-tumor macrophages/microglia, 543
 surgery and radiation, 544–545
 targeted therapy, 546–548
 therapeutic synergy, 550
 tumor microarray, 542
 VEGF pathway, 540
 whole brain radiation therapy, 544
- Melanomagenesis, 304
- Metabolism
 amino acid, 110–112
 definition, 100
 glucose, 110
 lipid, 112–113
 melanocyte, 104
 oxygen, 104
 ROS and mitochondrial, 114–116
 sugar, 108–110
- Meta-data, 602
- Metastatic adenopathy, 563
- Metastatic melanoma, 519, 520, 522, 524,
 526–528, 536, 539, 540–543, 546–549
 chemotherapy, 799
 staging, 489–492
 immune checkpoint inhibitor, 654–661, 800–802
 interleukin-2, 800
 irAEs (*see* Immune-related adverse events (irAEs))
- Methylated-CpG island recovery assay (MIRA)-seq, 87
- Methylated DNA immunoprecipitation (MeDIP), 87
- 5-Methylcytosine (5-mC), 85
- Microbiome
 cancer therapy, 292–295
 diarrhea, 297
 FMT, 297–298
 gut, 289
 in melanoma, 295–297
 profiling, 292
 skin, 289–292
- Microenvironment, 108, 113, 116
- Microphthalmia-associated transcription factor (MITF),
 25, 32, 33, 35, 39, 88, 588
 E318K MITF mutations, 588
- MicroRNAs (miRNA), 94, 642–643
- Microsatellites, 491
- Miescher's nevi, 340
- Minichromosome maintenance proteins (MCM), 200
- Missing heritability, 238–239
- Mitogen-activated protein kinase (MAPK) pathway,
 64–67, 84, 537–538, 745, 755, 759, 760, 774
- Mitotic rate, 488–489
- Molecular targeted therapy, 808–811
- Molemapper™ app, 617
- Mouse, 305
 melanoma models, 305
 xenograft models, 305–321
- mT/mG mouse line, 310
- ^{99m}Tc and indocyanine imaging agent, for sentinel
 lymph node detection, 566
- ^{99m}Tc-tilmanocept, 562
- Mucosal melanoma (MM), 136, 264–265
 clinical presentation, 443–444
 epidemiology, 442–443
 pathogenesis, 446
 radiation, 448–449
 surgery, 447–448
 systemic treatment, 449–450
 tumor behavior, 444–446
- Multicenter Selective Lymphadenectomy
 Trial (MSLT-I), 510–511
- Multicenter Selective Lymphadenectomy
 Trial (MSLT-II), 512
- Multiple CMN, 389
- Multispectral optoacoustic imaging (MSOT), 567
- MutSig, 191
- Myeloid derived suppressor cells (MDSCs), 654
- N**
- Nab-paclitaxel, 691
- Naevus spilus, 370
- National Comprehensive Cancer Network
 (NCCN), 518
- Nephritis, 807
- Neural crest, 4
 in vivo, 6
- Neural crest stem cells (NCSCs), 4, 5
- Neurocutaneous melanosis, 345
- Neuroid bodies, 380
- Neuroid type proliferations, 374
- Neurologic toxicity, 806

- Neurotization, 375
 Neurotropic DM (NDM), 720
 Neurotropism, 473, 475, 477, 478, 480
 Nevus (nevi), 250, 254, 256, 260, 263, 267, 339–351
 blue nevi, 349
 common acquired and dysplastic nevi, 339
 congenital nevi, 345, 365–391
 Spitz, 133, 396–399, 402–405, 426
 Nevus number, 234–236
 Next generation (massive parallel) sequencing, 292, 495, 658
 limitations, 640
 in molecular diagnostics, 638–640
 prognosis, 640
 NF1 gene, 167, 168, 680–681
 Nivolumab, 656, 658, 797
 Nodular melanoma, 353
 Non-coding RNAs (ncRNAs), 84, 94
 Non-invasive gene expression testing, 641
 Non-mammalian melanoma
 models, 323, 325
 Non-nodal locoregional disease, 491
 Non-steroidal anti-inflammatory drugs (NSAIDs), 762
 NRAS, 312, 314, 315, 319, 320, 416, 456
 mutated melanomas, 677
 mutations, 167
NUAK2, 416
 Nucleotide excision repair (NER), 125
 Nursing care, 812
 Nutrients, 100, 103, 104, 107, 111, 116, 117
- O**
 Ocular melanoma, 252, 264–267
 Ocular toxicities, 777–778, 807
 Oncology nurse, 793
 adverse event management, 808
 coordination, 793
 immunotherapy, 800
 management strategies, 801
 role of, 795, 799
 Oncolytic viral therapy, 786
 Oncolytic viruses, 657
 Optoacoustic imaging, 567
- P**
 Palliative wound care, 813
 Panniculitis, 762
 Paranasal sinus, 442, 444
P14arf/CDKN2A, 586
PARK2, 239
 Paronychia, 758–759, 764
 Passenger mutation, 183
 Patient-derived xenografts (PDX), 305, 306
 Pattern recognition, 601
 Pelvic computed tomography (CT) scans, 576
 Pembrolizumab, 797
 Pheomelanin, 25
 Phosphatase and tensin homologue (PTEN), 68, 69, 71, 85
 Hamartoma syndrome, 589
 phosphatidylinositol 3'-kinase (PI3K), 67–69
 Phosphatidylinositol 3-kinase-protein kinase B (PI3K-AKT) pathway, 538–539
 Photo acoustic imaging, 560, 567
 Photoproducts, 54, 56
 Photoprotection, melanoma prevention, 58
 Photosensitivity, 761, 765
 Phototoxicity, 766
 Pigmentation, 22, 23, 26, 29, 30
 eye, 32
 genetics, 232–234
 facultative, 40
 hair, 30
 and melanomagenesis, 43
 molecular pigment, 34
 skin, 30
 Pigmented lesions, mucosa
 melanotic macule, 440–441
 multifocal pigmentation, systemic causes of, 441–442
 neoplastic pigmentation, 442
 oral melanoacanthoma, 441
 reactive pigmentation, 441
 smoker's melanosis, 441
 Pigmented spindle cell nevus
 dermoscopy, 398
 histopathology, 398
PLX3603, 170
 Pneumonitis, 803–804
 Point mutations, 124–127
 Polycomb repressive complex (PRC), 93
 Post-zygotic mosaicism, 372
POT1, 587
PRAME, 456, 643
 Predictive biomarkers, 719
 Prenatal nevi, 370
PREX, 69, 71
 Primary tumor assessment
 mitotic rate, 488
 tumor thickness, 486–488
 ulceration, 488
 Prognostic biomarkers, 720
 Programmed death 1 (PD-1), 731, 745
 Proliferation, 304, 312, 313, 315, 316, 318, 320, 324
 Proliferative nodules, 346, 349, 635, 645
 CMN, 374, 382
 Protection of telomeres 1 (*POT1*), 229
 Pruritus, 747–752
 Psoriatic T cell, 291
 Pulmonary toxicity, 783
PV-10 (Provectus, Inc.), 526
 Pyrexia, 776

R

Rac signaling pathway, 70–71
 Radial base machine (RBM) modeling, 201, 720
 Radiation recall dermatitis, 761–762
 Radiation sensitivity, 761–762
 Radiotherapy, 477–478, 652, 720–721
 RAF inhibitors, 169
 paradox, 173–174
 RAF kinase, 167
 RANO criteria, 573
 RAS, 64, 66, 67, 167
 activation, 167
 GTPase activity, 168
 Ras associated domain family protein
 1A (RASSF1A), 86
 Rash, 747, 756, 763
 Reactive oxygen species (ROS), 126
 RECIST criteria, 572
 Recurrence risk, 795
 Refractory pruritus, 388
 Regional lymph nodes
 basins, clinical exam, 490
 lymphatic mapping technique, 490
 SLN biopsy, 490
 Regional metastasis, sentinel lymph node biopsy, 563
 Regorafenib, 170
 Resistance, 168, 174–175, 177
 Retinal pigment epithelium (RPE), 458
 Reverse transcriptase polymerase chain reaction
 (RT-PCR)-based techniques, 494
 Rhabdomyosarcoma, 378
 Rho proteins, 70
 Rigvir, 708
 Risk Factors for cutaneous
 melanoma, *see* Cutaneous melanoma
R26R-Confetti, 7
 rs498136, 237

S

Satellite lesions, 153, 491
 Satellite nevi, 370
 Scalp CMN, 374
 Senescence, 304, 305, 312, 313, 315, 319, 320
 Sentinel lymph node biopsy, 477
 DeCOG-SLT study, 511
 lymphoscintigram, 509, 510
 MSLT-I, 510–511
 MSLT-II, 512
 prognostic factors, 510
 technique of, 508–510
 Serum marker addition, in melanoma
 surveillance, 577
 Severe cutaneous adverse reactions
 (SCARs), 754–755
 SF3B1, 456
 Shelterin complex mutations, 229
 Short chain fatty acids (SCFAs), 289
 Sicca syndrome, 806

Signal cell RNA sequencing (scRNA seq), 659
 Signaling
 cell, 100, 104
 pathways, 104
 and senescence, 106–108
 Single nucleotide polymorphisms (SNP), 631, 641
 Single photon imaging method, 561
 Skin cancer prevention, 273, 275, 278
 Skin microbiota
 autoimmune disorder, 291
 psoriasis, 291
 Skin-related adverse events, 802
 Skin toxicity, 777
 SLN biopsy, 490
 Society for Immunotherapy of Cancer (SITC), 660
 Solar UV index, 273
 Solitary CMN, 388–389
 Sorafenib, 170
 Sox10, 9
 SPECT/CT-aided sentinel lymph node excision
 (SLNE), 564, 565
 Spitz nevus, 630, 631, 633, 635, 637, 642, 645
 atypical spitz tumor, 399
 characteristic features, 396
 classification, 396
 clinical appearance, 397
 clinical features, 396–397
 clinical management, 398–400
 description, 396
 genetics, initiating events in, 401–402
 histopathologic features and subtypes, 397–398
 HRAS, 402
 kinase fusions, 402–403
 secondary genetic alterations, 403
 targeted therapy, 406
 Spitzoid melanoma, 399, 402, 405
 Spitz tumors, 133
 Squamous cell carcinomas (SCC), 759, 760
 SRS, *see* Stereotactic radiosurgery (SRS)
 16s sequencing, 292
 Stereotactic radiosurgery (SRS), 545
 Steven Johnson syndrome (SJS), 751, 754, 756
 Suberoylanilide hydroxamic acid (SAHA), 92
 Sunbeds, 278
 Sunscreen, 276
 Superficial spreading melanoma (SSM), 353
 Supervised learning, 602
 Surveillance, Epidemiology, and End Results (SEER),
 251, 256, 264, 265
 Survival, 252, 255–257, 263, 265, 266
 Swine melanoma models, 323

T

Talimogene laherparepvec (T-VEC), 525, 657,
 700, 707, 730, 811
 Tanning, 23, 35, 39, 40, 44, 46
 Tardive CMN, 370
 Targeted screening program, 281

- Targeted therapy, 652, 660, 755–757
 BRAF + MEK inhibition, 688
 BRAF, 546, 548
 vs. BRAF inhibitor monotherapy, 774
 characteristics, 668
 clinical trials, 546
 dabrafenib, 546
 dabrafenib and trametinib
 combinations, 774
 epidermal tumors, 759–760
 folliculitis and acneiform rash, 758
 hair changes, 759
 hand-foot reaction (hyperkeratosis),
 760–761, 763
 and immuno-oncology, 175
 and immunotherapy combination, 689
 KIT inhibitors, 175–176, 681–683
 MAPK pathway, 547
 MEK and ERK inhibitors, 172–173
 MEK inhibition, 673
 melanocytic proliferations and
 new primary melanomas, 760
 melanoma genetics, 668–670
 NF1 loss of function, 680–681
 NRAS mutated melanomas, 677–680
 panniculitis, 762
 paronychia, 758–759, 764
 photosensitivity, 761
 PI3K-AKT pathway, 547
 radiation sensitivity and radiation
 recall dermatitis, 761–762
 RAF inhibitors, 169–172
 RAS, 167–168
 rash, 756
 with BRAF/MEK inhibitors, 737
 TAZ, 75
 T-cell receptor (TCR), 653, 654, 661
 Tcf/Lef family, 12
 Technology literacy, 617
 Tele dermatology, 617
 Teledermoscopy, 617
 Telomerase activity, 141–142
 Telomerase reverse transcriptase
 gene (*TERT*), 229, 403–404, 415, 587
 Telomere related genes, 587
 Telomeres, 228–230
 Ten eleven translocation
 (TET) proteins, 88
TERF2IP, 230, 587
 5' Terminal oligopyrimidine
 tract (5'TOP), 189
 The Cancer Genome Atlas (TCGA), 84
 THxID™, 808
 Thyroid dysfunction, 805
 TNM staging system vs. risk assessment, 496
 Total body skin exams (TBSE), 594
 Toxic epidermal necrolysis (TEN),
 751, 754, 756
 Trametinib, 798
 Transforming growth factor beta
 (TGF-beta), 660
 T regulatory cells (T regs), 654
Triple WT melanomas, 192
 Tumor cell of origin, 14
 Tumor infiltrating lymphocytes
 (TIL), 661
 Tumor microarray (TMA), 542
 Tumor mutational burden (TMB), 658
 Tumor tropism, 702–703
 Type 1 diabetes, 805
- U**
 Ulceration, 488
 Ulixertinib, 173
 Ultrasound, sentinel lymph nodes, 566
 Ultraviolet radiation (UVR), 22, 52,
 54, 56, 58, 273
 exposure, 339
 Unna's nevus, 340
 Unsupervised learning, 603
 UVB, 53, 54, 57
 Uveal melanoma, 209
 clinical features, 458
 copy number variations, 210
 cytogenetic abnormalities, 457
 first generation sequencing, 209–210
 future studies, 214–216
 gene expression profile, 456
 histopathology, 457, 458
 incidence of, 454
 metastatic disease, 463
 molecular pathology, 455–456
 mRNA/miRNA expression profiling, 211
 next-generation sequencing, epigenetics and
 integrative analysis, 211–214
 ocular investigations, 460
 prognostication, 462, 463
 systemic investigations, 463
 treatment, 461
 treatment of metastatic disease, 464
 UV-signature mutations, 54, 57
- V**
 Variant of uncertain significance (VUS), 593
 Vascular endothelial factors
 (VEGFs), 150, 152, 158, 540
 receptors (VEGFRs), 170
 Vemurafenib, 170, 171
 and ipilimumab combination, 690
 Viral-based therapy, 700
 Viral vaccines, 704–706
 Virus-engineered dendritic cells, 710
 Vitamin D resistant rickets, 378
 Vitiligo, 750, 752–753
 Vorinostat, 92
 Vulvovaginal mucosa, 440

W

Wegner-Meissner bodies, 380
Whole body imaging, metastatic disease
 identification, 559
Whole brain radiation therapy
 (WBXRT), 544, 545
Whole genome copy number analysis, 386
Whole metagenomic sequencing (WMS), 292
Wide local excision, 506, 508, 510, 511
Wnt/ β -catenin, 12
Wnt signaling pathway, 72–75

X

Xerostomia and mucositis, 806

Y

Yes associated protein, 70

Z

Zebrafish, 324, 325
Z/EG mouse line, 310